Other analysts have also recently issued reports about the stock. Zacks Investment Research upgraded shares of Mesoblast from a hold rating to a buy rating and set a $6.25 price objective for the company in a research note on Saturday, January 13th. Oppenheimer set a $16.00 price objective on shares of Mesoblast and gave the stock a buy rating in a research note on Wednesday, December 20th. Finally, Cantor Fitzgerald set a $20.00 price objective on shares of Mesoblast and gave the stock a buy rating in a research note on Tuesday, January 16th. Two analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of Hold and a consensus target price of $13.11.
Shares of Mesoblast (MESO) traded up $0.11 during trading on Thursday, hitting $6.19. 78,043 shares of the stock were exchanged, compared to its average volume of 53,769. Mesoblast has a twelve month low of $4.74 and a twelve month high of $12.50.
A hedge fund recently bought a new stake in Mesoblast stock. Princeton Capital Management LLC bought a new stake in shares of Mesoblast limited (NASDAQ:MESO) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 124,022 shares of the company’s stock, valued at approximately $724,000. Princeton Capital Management LLC owned about 0.13% of Mesoblast at the end of the most recent reporting period. Institutional investors and hedge funds own 2.74% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://transcriptdaily.com/2018/02/25/mesoblast-meso-given-a-14-00-price-target-at-maxim-group.html.
Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.